HeartBeam Inc. has developed a revolutionary cable-free ECG system, the HeartBeam AIMIGo™, which captures the heart's electrical signals in three dimensions. This credit card-sized device synthesizes a 12-lead ECG, providing a comprehensive assessment of heart activity without the need for trained healthcare professionals. The technology allows patients to record their ECGs conveniently at home, capturing symptoms as they occur. The recorded data is then sent to the HeartBeam cloud for analysis, where on-call physicians can review the recordings and provide timely follow-up care. This innovative approach aims to enhance the accuracy of heart health monitoring and facilitate informed diagnosis and care for conditions such as arrhythmias.

In addition to its user-friendly design, HeartBeam's technology leverages artificial intelligence (AI) to analyze the data collected, improving diagnostic accuracy and enabling the tracking of cardiac trends over time. The system is designed to detect complex arrhythmias and provide personalized cardiac insights, potentially replacing traditional 12-lead ECGs as the standard of care. With a strong foundation of 13 US patents and the potential for broad applications, HeartBeam's technology represents a significant advancement in cardiac care, promising to deliver earlier and more precise management of heart health.

United States

HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming cardiac care by providing powerful insights wherever the patient is. The Company is creating the first ever cable-free 12-lead ECG capable of capturing the heart’s electrical signals from three dimensions. 

HeartBeam Inc. (NASDAQ: BEAT)

Company Details